Telemedicine Technology Joint Venture Announced Between Cytta Corp and Cardiocomm Solutions

HeartCheck™ and GEMS™ ECG Technologies to be adopted onto the EvrCare™ Health and Wellness Platform

Palm Desert, CA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cytta Corp. (OTCPINK:CYCA), a leading provider of mobile smartphone and web based healthcare technology solutions, and CardioComm Solutions, Inc. (“CardioComm”) (TSX VENTURE:EKG), a Canada based global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software and hardware solutions, today announced completion of a Joint Venture Agreement (“Agreement”).

Under the announced Agreement both parties will integrate their respective technologies to implement a comprehensive, mobile telemedicine communication and connectivity health and wellness portal solution by building on Cytta’s EvrCare™ branded VeriSmartPhone™ web-based remote patient monitoring platform. The EvrCare™ solution also leverages Cytta’s innovative video and data compression/decompression solution known as SUPER™ (Superior Utilization of Processing for Error Resilience) which reduces data file size, improves speed of data transfers, lowers telemedicine communication costs and introduces a new level of data transmission security.

Cytta selected CardioComm as its preferred provider to augment their existing M-Health/telemedicine and IoT remote patient monitoring solution due to CardioComm’s expertise in supplying ECG monitoring devices, connectivity solutions and ECG reviewing software that are cleared as Class II medical devices by the US FDA and Health Canada regulatory authorities. CardioComm’s software as a medical device (“SaaMD”) ECG solutions are capable of accepting raw ECG data from any Bluetooth enabled ECG devices to generate an accurate ECG trace rendered on a scaled grid, delivered with information that is specific to the individual the ECG was recorded from as well as those who reviewed and reported the ECG findings.

All reports, findings and associated patient information would be managed within the EvrCare™ telemedicine platform which will incorporate CardioComm’s ECG analysis tools and provide the ECG findings along with data from all other EvrCare™ connected health and wellness peripherals that were used to monitor patients or used by consumers for self-monitoring. Cytta was also drawn to CardioComm’s potential to add multiple bio-sign monitoring under their Class II medical device clearances and thereby potentially cover the EvrCare branded platform services under a SaMD classification.

The completed ErvCare™ solution is expected to provide single users as well as group plan operators the ability to track, evaluate and manage biometric information seamlessly, concurrently and in “real-time” from all connected health and wellness devices. Cytta’s plans to incorporate a ‘doctor directed’ platform where devices themselves can be prescribed by caregivers and insurers to improve long term care in managing people at high risk for disease onset and those living with chronic medical conditions. Cytta anticipates the addition of the CardioComm ECG hardware and software to the EvrCare™ platform will provide a valuable and potentially lifesaving functionality to US healthcare consumers.


The EvrCare™ and ECG development work are intended to be the first phase of a multiphase program between CardioComm and Cytta’s IOT telemedicine solutions. Incorporation of CardioComm’s ECG monitoring capabilities will help to remove many of the technological, work flow and infrastructure challenges that exist in remote patient monitoring solutions for mobile cardiac telemetry, arrhythmia and prolonged QT interval screening and serve to expand EvrCare’s service offerings.

In addition to consumer offerings the technology may be expanded to include in-hospital and in-clinic services, pre/post-hospital surgery discharge monitoring and to support long-term and managed care groups in monitoring the insured lives of people living with chronic medical conditions.

Cytta plans the EvrCare™ telemedicine platform with ECG management capabilities will be initially deployed in the USA.

About Cytta Corp

Cytta Corp's business model entails developing and securing disruptive technologies to build credible and industry specific data collection and communication solutions for use by enterprise level organizations who can implement the technologies into their specific industry segments. In keeping with this goal, Cytta has developed the EvrCare™ platform to address the market need for a complete and comprehensive automatic monitoring, evaluation and interpretation solution to manage a wide range of biometric data, including ECGs, within military, consumer, wellness and healthcare markets. Specifically, Cytta Corp. develops and integrates technologies in the smartphone, compression and mobile broadband markets. Cytta’s EvrCare™ technology itself consists of several disruptive and proprietary technology advances including cloud based data server host stacking, a proprietary android control interface (“PACI”) operating system software, the VeriSmartPhone™ application, online interactive and a HIPPA compliant patient/physician/health-plan administrator communication dashboard.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients.  Products are sold worldwide through a combination of an external distribution network and a North American-based sales team.  The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada. 

Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227

 Safe Harbor Statement/ Forward-Looking Statements

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks. Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward looking statements, whether as a result of future events, new information, or otherwise.


Contact Data